Paris, France – Aug. 30, 2011: Results from a study presented today at the ESC Congress 2011, show that TAVI implantation in low risk patients, met with 100% procedural success (versus 95.3% in the high Euroscore group (p=0.1).
“The most interesting point to observe is the absence of death at one month in the low Euroscore group, versus a mortality rate of 11.1% in the high Euroscore group (>20%), (p < 0.04) and this result is confirmed at 1-year with 5 vs 24.8 %, (p<0.01). While we were expecting a lower mortality among patients with low Euroscore, the observed difference was much greater than anticipated. In fact the mortality rates have approached the results with conventional surgery,” explained Dr Matthieu GODIN, from the University Hospital of Rouen, France.
Aortic stenosis is the most frequently acquired valve disease in adults. 2% are symptomatic and thus should require aortic valve replacement because, in this disease, a long latency is followed by rapid progression after the appearance of symptoms, with more than half of patients dying within two years. It can be estimated that with the aging population, within 15 years, the number of aortic stenosis patients will double.
After more than 15 years of research, the first-in-man percutaneous valve implantation was performed in our center at the University Hospital of Rouen by Prof. Cribier in April 2002. Since then, about 40 000 patients have been implanted worldwide with the use of two different models of valve: the balloon expandable valve 1 and the self expanding device 2. The CE mark was obtained for both in 2007. TAVI can today be proposed as an alternative treatment and has recently demonstrated its great efficiency with the results of the pivotal PARNER-US trial. Based on the recommendations of both the European Society of Cardiology and the European Society of Cardiac Surgery, most of the registries have so far only included patients with high logistic Euroscore > 20%. (a system developed to predict the operative mortality of coronary surgery).
In view of the overall good results in this high risk population, a significant trend to include lower risk patients in Europe has been observed. The last registries have seen their Euroscore decreasing to 15% and some prospective trials are planned to include patients whatever their Score.
“We sought to evaluate the results obtained in our subgroup of patients with a low Euroscore. It does not mean that the patients were at very low risk for TAVI, since they had been considered as having surgical contraindication which did not affect the Euroscore (radiotherapy, corticosteroids, thoracic deformation or porcelain aorta). However, the patients were often less sick and younger and it seemed interesting to assess the results in this population,” said Dr Godin.
This study is a retrospective study from all 177 patients implanted with the Edwards prosthesis at the Rouen centre between May 2006 and January 2011. Patients were divided into two groups according to their predictive Logistic Euroscore: High Euroscore (>20%) vs Low Euroscore (<20%).
Results show that procedural success was 100% in the low Euroscore group versus 95.3% in the high Euroscore group (p=0.1).
The most interesting point to observe is the absence of death at one month in the low Euroscore group, versus a mortality rate of 11.1% in the high Euroscore group (>20%), (p < 0.04) and this result is confirmed at 1-year with 5 vs 24.8 %, (p<0.01)
While we were expecting a lower mortality among patients with low Euroscore, the observed difference was much greater than anticipated. In fact the mortality rates have approached the results with conventional surgery.
The results represent a first step towards a broader assessment of percutaneous techniques in populations at lower surgical risk but without forgetting that surgery is currently the gold standard.
Contributors: Dr Matthieu Godin, Pr Hélène Eltchaninoff, Pr Alain Cribier
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2011. Transcatheter aortic valve implantation with the Edwards valve prosthesis in patients with low (<20%) logistic euroscore: results of a prospective single center registry The press release has been written by the investigator and edited by the ESC and does not necessarily reflect the opinion of the European Society of Cardiology.
About the European Society of Cardiology The European Society of Cardiology (ESC) represents more than 68,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2011 ESC Congress 2011 will take place from 27 to 31 August at the Parc des Expositions - Paris Nord Villepinte, France. Information on the scientific programme is available here. More information on ESC Congress 2011 is available from the ESC Press Office or contact us at email@example.com
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved